Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Treatment for cancer can cause unwanted side effects affecting the skin that may be associated with itching or pain. These side effects may have a direct link to the immune system's response to cancer.
Their tumors are also mismatch repair proficient (MMRp)/microsatellite stable (MSS). MMRp/MMS means that their cells are working normally to repair any mistakes made during cell division.
Researchers want to see how well volrustomig works to treat people with inoperable head and neck squamous cell cancer (HNSCC). Inoperable means the cancer cannot be taken out with surgery. The people in this study have HNSCC that has not grown after chemotherapy and radiation given at the same time.
A mutation called G12C in a gene called KRAS may promote cancer growth. LY3537982 is an investigational drug that targets the mutated KRAS G12C protein. This targeting action may stop cancer cells from growing and dividing.
The usual care for people with squamous cell skin cancer is surgery, with or without radiation therapy. Sometimes the cancer comes back (recurs). For this reason, researchers are studying other treatments for squamous cell skin cancer.
When some cancers become advanced, particularly colorectal cancer, they may spread to the liver. Destroying the tissue with electromagnetic waves that produce extremely high temperatures, a procedure called "thermal ablation," is one way to treat these liver metastases.
Researchers are assessing ado-trastuzumab emtansine (T-DM1) to treat salivary gland cancer. The people in this study have cancer that is operable (can be removed with surgery) and makes a protein called HER2. T-DM1 targets cancer cells that make HER2. In this study, it will be combined with radiation therapy and chemotherapy after the tumor has been removed by surgery.
The purpose of this study is to assess the safety and effectiveness of the drug trastuzumab deruxtecan (also known as DS-8201A) in patients with inoperable or metastatic solid tumors that produce too much of a protein called HER2, including biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers.
The purpose of this study is to see how treatment for retinoblastoma in one eye affects quality of life in survivors of this cancer who had chemotherapy (injected into the eye) or surgery to remove the eye. Researchers will ask participants about their physical and emotional health and ability to perform daily activities. They want to determine if there are any differences between these treatments with respect to their effect on quality of life. It is hoped that this information will help doctors provide better care for children with retinoblastoma in the future and better follow-up care for survivors of this cancer.
Researchers want to see how well tebentafusp works in people with clear cell sarcoma that has spread. This cancer grows deeply into soft tissues of the arms and legs. The people in this study have clear cell sarcoma that is inoperable (cannot be surgically removed) or has spread.
